Monday
08.19.2019
12:55 PM
Login form
Search
Calendar
Entries archive

My site

Main » 2018 » December » 04

WASHINGTON-Saturday 1 December 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- PSB, a global research-based consultancy, announced today that Char Popp has joined the firm as Senior Vice President and Global Head of Qualitative Research to oversee the growth and development of the firm’s Qualitative Research offerings. She is based in Seattle and holds global responsibilities.

Popp is a veteran in strategic research and marketing strategy, having worked both in-house and as adviser to the technology industry for nearly 20 years. Her expertise lies in qualitative research where she has been responsible for driving customer, product and market strategy across a broad range of clients and industries via new methods and new research modes – including facilitated co-creation and product design sessions – all with a focus on end results that drive business impact. Popp’s hire is part of an approach to marry PSB’s depth of expertise in data analytics wit ... Read more »

Views: 40 | Added by: africa-live | Date: 12.04.2018 | Comments (0)

SUMMIT, N.J. -Monday 3 December 2018 [ AETOS Wire ]


Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo

Positive trend in overall survival was observed

Regulatory submissions planned for Q1 2019

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced results of the phase 3 AUGMENT study, which showed that REVLIMID® (lenalidomide) in combination with rituximab (R2) demonstrated superior progression-free survival (PFS) in patients with relapsed/refractory indolent lymphoma compared to patients who received rituximab plus placebo (R-placebo). The data were presented by John Leonard, M.D. in an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, C.A. (Abstract #445).

The phase 3 randomized, double-blind, international clinical study evaluated the efficacy and safety of the investigational ... Read more »

Views: 30 | Added by: africa-live | Date: 12.04.2018 | Comments (0)

Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo

Regulatory submissions planned in the United States and Europe in the first half of 2019

SUMMIT, N.J. & CAMBRIDGE, Mass.-Monday 3 December 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspatercept to treat patients with ring sideroblast (RS+) myelodysplastic syndromes (MDS)-associated anemia who require red blood cell transfusions and who had failed, were intolerant to, or ineligible for erythropoietin therapy. Results were presented by Alan F. List, M.D. during the Plenary Scientific Session at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, C.A. ... Read more »

Views: 30 | Added by: africa-live | Date: 12.04.2018

Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in significant reduction of transfusion burden compared to placebo

Regulatory submissions planned in the United States and Europe in the first half of 2019

SUMMIT, N.J. & CAMBRIDGE, Mass. -Sunday 2 December 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated anemia who require regular red blood cell (RBC) transfusions. The data were presented by Maria Domenica Cappellini, M.D. in an oral session of the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (Abstract #163).

“Currently, the standard of care to help patients with beta-thalassemia manage their anemia is reg ... Read more »

Views: 29 | Added by: uaeonlinenews | Date: 12.04.2018

Leading energy provider in Japan maximizes ROI on key SAP system while receiving premium-level support


LAS VEGAS-Saturday 1 December 2018 [ AETOS Wire ]

(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that Tokyo Gas Co., Ltd., Japan’s largest provider of city gas, has switched to Rimini Street support for its SAP BusinessObjects application. By switching to Rimini Street support, Tokyo Gas finds it now receives a vastly improved service model which is more comprehensive and responsive than what they had received before; the company can also maximize its current, stable SAP application without the need to upgrade just to stay fully supported, for a minimum of 15 years from the time the company transitioned to Rimini Street. Additionally, Tokyo Gas has realized significant savings in total ... Read more »

Views: 35 | Added by: africa-live | Date: 12.04.2018